Dabigatran
Brand: Pradaxa (US/EU) / Dabistar (IN) / Drabi (IN/BD)
Anticoagulant
NOAC / DOAC (Thrombin IIa inhibitor)
Pharmacokinetics
| Half-life | 12 hours |
| Tmax | 2 h |
| Bioavailability | 7 % (approx) |
| Protein Binding | 35 % |
| Volume of Distribution | 0.5 L/kg (approx) |
| Clearance Route | renal |
| Active Metabolites | no |
| Notes | Requires acidic environment for absorption (formulated with tartaric acid); avoid in severe renal impairment; fully reversible by Idarucizumab. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Bleeding (GI > cerebral), dyspepsia, gastritis-like symptoms due to acidic core, rare hypersensitivity
Contraindications:
Mechanical heart valves, severe renal impairment (CrCl <30), active bleeding
Precautions:
Use caution in elderly/renal impairment; reversal agent = Idarucizumab; swallow capsule whole (do not open)